Clinical Trial Update: Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

View source ↗

Summary

The document notes that pirtobrutinib is approved for marketing in relation to an expanded access program for multiple B-cell cancers, covering several indicati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Richter Transformation
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: Loxo Oncology, Inc. | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Lymphocytic, Small | Status: APPROVED_FOR_MARKETING